CRISPR Therapeutics’ (CRSP) Buy Rating Reiterated at Needham & Company LLC

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a report released on Tuesday, Benzinga reports. They currently have a $82.00 price objective on the stock. Needham & Company LLC‘s price target points to a potential upside of 64.03% from the stock’s previous close.

Several other research firms also recently issued reports on CRSP. Citizens Jmp reaffirmed a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a report on Monday, August 31st. William Blair raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. UBS Group started coverage on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. They set a “neutral” rating and a $52.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Thursday, October 15th. Finally, Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $65.75.

CRISPR Therapeutics Trading Down 2.8%

Shares of CRSP stock opened at $49.99 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. The company has a market cap of $4.83 billion, a price-to-earnings ratio of -10.50 and a beta of 1.76. The stock has a 50 day simple moving average of $54.00 and a 200-day simple moving average of $52.89. CRISPR Therapeutics has a 1-year low of $44.12 and a 1-year high of $64.74.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.11). The company had revenue of $12.67 million during the quarter, compared to analyst estimates of $14.75 million. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. On average, equities research analysts expect that CRISPR Therapeutics will post -4.44 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, Director Ali Behbahani sold 13,679 shares of the stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the sale, the director directly owned 16,637 shares in the company, valued at $949,806.33. This represents a 45.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 47,837 shares of the firm’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the completion of the transaction, the chief executive officer directly owned 311,899 shares in the company, valued at approximately $15,526,332.22. This represents a 13.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 93,558 shares of company stock worth $4,881,663 over the last three months. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Swiss National Bank grew its position in shares of CRISPR Therapeutics by 5.1% in the first quarter. Swiss National Bank now owns 169,700 shares of the company’s stock valued at $8,073,000 after purchasing an additional 8,200 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in CRISPR Therapeutics during the first quarter worth approximately $7,136,000. Congress Asset Management Co. lifted its position in CRISPR Therapeutics by 1.6% during the third quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock worth $6,153,000 after buying an additional 1,777 shares in the last quarter. KBC Group NV boosted its stake in CRISPR Therapeutics by 3,999.9% during the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock worth $5,558,000 after buying an additional 113,997 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in CRISPR Therapeutics by 29.6% during the first quarter. California State Teachers Retirement System now owns 101,232 shares of the company’s stock worth $4,816,000 after buying an additional 23,109 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY sales accelerated: Third-quarter CASGEVY revenue reached $99 million, up 30% sequentially and nearly sixfold from the year-earlier period. The therapy also received expanded pediatric approvals in the U.K., United Arab Emirates and Bahrain, improving its commercial opportunity. CRISPR Therapeutics Third-Quarter 2026 Results
• Positive Sentiment: Pipeline progress: The FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. The company also expects to present CTX310 and zugo-cel clinical data at upcoming medical conferences and completed enrollment in a Phase 2 CTX611 trial. These developments could provide future catalysts. CRISPR Therapeutics Business Update
• Neutral Sentiment: Brokerage view remains a focus: Recent coverage reviews what analysts and brokerages think about CRSP, but the available report details do not identify a major change in consensus ratings or price targets. Brokerage Views on CRISPR Therapeutics
• Neutral Sentiment: Manufacturing leadership added: CRISPR appointed Siva Sakhamuri, Ph.D., as chief technical officer. His experience in biologics, vaccines, oligonucleotides, RNA therapeutics and lipid nanoparticles may support commercialization, but the appointment is unlikely to materially affect near-term earnings. CRISPR Therapeutics CTO Appointment
• Negative Sentiment: Quarterly results missed expectations: CRISPR reported a third-quarter loss of $1.15 per share versus the roughly $1.04 analyst consensus, while revenue of $12.67 million fell short of estimates near $14.75 million. The company remains deeply unprofitable and continues to depend heavily on its cash reserves to fund its costly development pipeline. CRISPR Therapeutics Earnings Flash

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.